<code id='07E812DFD8'></code><style id='07E812DFD8'></style>
    • <acronym id='07E812DFD8'></acronym>
      <center id='07E812DFD8'><center id='07E812DFD8'><tfoot id='07E812DFD8'></tfoot></center><abbr id='07E812DFD8'><dir id='07E812DFD8'><tfoot id='07E812DFD8'></tfoot><noframes id='07E812DFD8'>

    • <optgroup id='07E812DFD8'><strike id='07E812DFD8'><sup id='07E812DFD8'></sup></strike><code id='07E812DFD8'></code></optgroup>
        1. <b id='07E812DFD8'><label id='07E812DFD8'><select id='07E812DFD8'><dt id='07E812DFD8'><span id='07E812DFD8'></span></dt></select></label></b><u id='07E812DFD8'></u>
          <i id='07E812DFD8'><strike id='07E812DFD8'><tt id='07E812DFD8'><pre id='07E812DFD8'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:comprehensive    Page View:54684
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In